Work

UK – mRESVIA RSV vaccine approved to protect patients aged 60 and over

Year: 2025

Type: other

Abstract: A study found that around 4 months after vaccination, people who received the RSV vaccine had a 79% reduction in their risk of getting lower respiratory tract disease caused by RSV, compared with those who received placebo. The Medicines and Healthcare products Regulatory Agency (MHRA) has approved an mRNA respiratory syncytial virus (RSV) vaccine (brand name mRESVIA) to protect patients aged 60 and over against lower respiratory tract disease caused by RSV. RSV is a common virus that spread...

Source: Industrias Culturais (Universidade de Coimbra)

DOI: 10.58079/13xyf

Author: Vroby

Language: English

Topic: Respiratory viral infections research

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W6974470009

Cites:

Cited by:

Related to: